id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-342873-eu7f0zjm	Yeleswaram, Swamy	Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment	2020-06-23		.txt	text/plain	2885	147	44	Patients with severe COVID-19 experience elevated plasma levels of pro-inflammatory cytokines, which can result in cytokine storm, followed by massive immune cell infiltration into the lungs leading to alveolar damage, decreased lung function, and rapid progression to death. Although most patients with COVID-19 experience only mild-to-moderate disease, approximately 15% progress to severe pneumonia, and 5% develop acute respiratory distress syndrome (ARDS), septic shock, and/or multiple organ failure, which can rapidly lead to death [3] . The high levels of pro-inflammatory cytokines lead to massive immune cell infiltration of the lungs in patients with COVID-19, resulting in alveolar damage, decreased lung function, and rapid progression to death [7, 8] . Ruxolitinib (INCB018424) is a selective inhibitor of JAK1 and JAK2 that is approved for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-J o u r n a l P r e -p r o o f Journal Pre-proof 6 host disease (SR-aGVHD) [15] .	./cache/cord-342873-eu7f0zjm.txt	./txt/cord-342873-eu7f0zjm.txt